Posted by Michael Wonder on 12 Oct 2020
Radiopharmaceutical cancer treatment Lutathera now available to Ontario patients with midgut neuroendocrine tumours
8 October 2020 - Lutathera is the first and only therapeutic radiopharmaceutical approved by Health Canada for the treatment of GEP-NETs.
Eligible cancer patients in Ontario midgut neuroendocrine tumours now have access to a new innovative radiopharmaceutical therapy, Lutathera (lutetium (177 Lu) oxodotreotide) from Advanced Accelerator Applications Canada.
This news addresses the need for additional treatment options for this life-threatening cancer affecting the neuroendocrine cells of the pancreas and gastro-intestinal tract.
